Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up
Aim. To evaluate the effect of biomarkers of inflammation on the long-term prognosis in patients with myocardial infarction (MI) and heart failure (HF) with preserved and mid-range ejection fraction according to a registry of percutaneous coronary interventions (PCI).Material and methods. A total of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691788990742528 |
|---|---|
| author | N. A. Musikhina T. I. Petelina A. I. Kostousova L. I. Gapon E. A. Gorbatenko I. S. Bessonov |
| author_facet | N. A. Musikhina T. I. Petelina A. I. Kostousova L. I. Gapon E. A. Gorbatenko I. S. Bessonov |
| author_sort | N. A. Musikhina |
| collection | DOAJ |
| description | Aim. To evaluate the effect of biomarkers of inflammation on the long-term prognosis in patients with myocardial infarction (MI) and heart failure (HF) with preserved and mid-range ejection fraction according to a registry of percutaneous coronary interventions (PCI).Material and methods. A total of 135 patients with MI included in the PCI registry in 2012-2013 were examined. Group 1 included 89 patients with HF with mid-range ejection fraction (HFmrEF) — 40-49%; group 2 included 46 patients with HF with preserved ejection fraction (HFpEF) — ≥50%. Biomarkers of inflammation were determined at admission to the hospital, after 12 and 60 months.Results. Eighteen people died during the follow-up period. The survival rate of patients in the compared groups after 60 months did not differ (group 1 — 85,0%; group 2 — 89,1%, p=0,492). Mortality predictors were the platelet count (HR, 1,011; 95% CI, 1,003-1,019; p=0,010), homocysteine level (HR 1,172; 95% CI, 1,008-1,364; p=0,040), MMP-9 >249 ng/ml (HR, 7,052; 95% CI, 1,346-36,950; p=0,021). In both groups there was a decrease in survival in patients with high levels of MMP-9 (>249 ng/ml). In group 1, mortality was higher among patients with platelet count >245*109/l. In both groups the levels of inflammatory markers exceeded the standard values for the entire period of follow-up. The dynamics of NT-proBNP, hs-CRP, TNF-α and homocysteine had a unidirectional pattern, in particular, a decrease in parameters after 12 months, followed by their increase after 60 months.Conclusion. Levels of MMP-9, homocysteine, and platelets were the factors that influenced 5-year survival in the general group of patients after MI and PCI. In the group with HFmrEF, MMP-9 and platelets had a negative impact on the prognosis. In patients with HFpEF, reduced survival was associated only with high levels of MMP-9. The dynamics of markers of systemic inflammatory response and NT-proBNP indicates the prolonged inflammatory process in both groups of patients, persisting for 5 years after MI. |
| format | Article |
| id | doaj-art-ecca88dd883b4a87bb6a6d2396030158 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2020-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-ecca88dd883b4a87bb6a6d23960301582025-08-20T03:20:55Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-12-01251210.15829/1560-4071-2020-37262926Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-upN. A. Musikhina0T. I. Petelina1A. I. Kostousova2L. I. Gapon3E. A. Gorbatenko4I. S. Bessonov5Tyumen Cardiology Research Center, Tomsk National Research Medical CenterTyumen Cardiology Research Center, Tomsk National Research Medical CenterTyumen Cardiology Research Center, Tomsk National Research Medical CenterTyumen Cardiology Research Center, Tomsk National Research Medical CenterTyumen Cardiology Research Center, Tomsk National Research Medical CenterTyumen Cardiology Research Center, Tomsk National Research Medical CenterAim. To evaluate the effect of biomarkers of inflammation on the long-term prognosis in patients with myocardial infarction (MI) and heart failure (HF) with preserved and mid-range ejection fraction according to a registry of percutaneous coronary interventions (PCI).Material and methods. A total of 135 patients with MI included in the PCI registry in 2012-2013 were examined. Group 1 included 89 patients with HF with mid-range ejection fraction (HFmrEF) — 40-49%; group 2 included 46 patients with HF with preserved ejection fraction (HFpEF) — ≥50%. Biomarkers of inflammation were determined at admission to the hospital, after 12 and 60 months.Results. Eighteen people died during the follow-up period. The survival rate of patients in the compared groups after 60 months did not differ (group 1 — 85,0%; group 2 — 89,1%, p=0,492). Mortality predictors were the platelet count (HR, 1,011; 95% CI, 1,003-1,019; p=0,010), homocysteine level (HR 1,172; 95% CI, 1,008-1,364; p=0,040), MMP-9 >249 ng/ml (HR, 7,052; 95% CI, 1,346-36,950; p=0,021). In both groups there was a decrease in survival in patients with high levels of MMP-9 (>249 ng/ml). In group 1, mortality was higher among patients with platelet count >245*109/l. In both groups the levels of inflammatory markers exceeded the standard values for the entire period of follow-up. The dynamics of NT-proBNP, hs-CRP, TNF-α and homocysteine had a unidirectional pattern, in particular, a decrease in parameters after 12 months, followed by their increase after 60 months.Conclusion. Levels of MMP-9, homocysteine, and platelets were the factors that influenced 5-year survival in the general group of patients after MI and PCI. In the group with HFmrEF, MMP-9 and platelets had a negative impact on the prognosis. In patients with HFpEF, reduced survival was associated only with high levels of MMP-9. The dynamics of markers of systemic inflammatory response and NT-proBNP indicates the prolonged inflammatory process in both groups of patients, persisting for 5 years after MI.https://russjcardiol.elpub.ru/jour/article/view/3726myocardial infarctionheart failuremarkers of inflammation5-year follow-up |
| spellingShingle | N. A. Musikhina T. I. Petelina A. I. Kostousova L. I. Gapon E. A. Gorbatenko I. S. Bessonov Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up Российский кардиологический журнал myocardial infarction heart failure markers of inflammation 5-year follow-up |
| title | Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up |
| title_full | Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up |
| title_fullStr | Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up |
| title_full_unstemmed | Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up |
| title_short | Biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction: 5-year prospective follow-up |
| title_sort | biomarkers of inflammation in patients with myocardial infarction and heart failure with preserved and mid range ejection fraction 5 year prospective follow up |
| topic | myocardial infarction heart failure markers of inflammation 5-year follow-up |
| url | https://russjcardiol.elpub.ru/jour/article/view/3726 |
| work_keys_str_mv | AT namusikhina biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup AT tipetelina biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup AT aikostousova biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup AT ligapon biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup AT eagorbatenko biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup AT isbessonov biomarkersofinflammationinpatientswithmyocardialinfarctionandheartfailurewithpreservedandmidrangeejectionfraction5yearprospectivefollowup |